Pharmaceutical compounds
US7750002B2 · kind B2 · utility
17Cited by
12References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2007 |
| Grant date | Jul 6, 2010 |
| Priority date | — |
| Expiry date | Jul 21, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fused pyrimidines of formula (I):wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof, have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.